Immunocompetence and Biologic Therapies: Assessing Risks and Preventing Complications from Infections

How to Obtain AMA PRA Category 1
Credit(s)™

  1. Watch the CME Webcast.
  2. Take the CME posttest.
  3. Login to your account.
  4. Complete the registration / evaluation form.
  5. Print your personalized CME certificate.

 

   

Panel Discussion - Immunocompetence and Biologic Therapies: Assessing Risks and Preventing Complications from Infections

Print this Content
Release Date: February 5, 2009 Expiration Date: February 5, 2010

Technical Requirements
(will appear in new window)

Estimated Time of Completion

30 minutes

Overview

Recently, there has been an increased focus on the impact of biologic agents on infectious complications and immunocompetence. Biologic agents are associated with a small but significant risk of certain types of infection, including common respiratory, skin, and soft tissue infections and several others. It is important for clinicians who use biologic therapeutics to be facile in the management of a wide array of infectious complications.

Another important educational need is how current and forthcoming biologic therapies affect immunologic memory and a patient's capacity to respond to an immunologic challenge.

These educational needs will be addressed in a series of presentations that focus on the following points.

  • The importance of assessing immunocompetence
  • The long-term relative risks of serious bacterial and opportunistic infections among biologics
  • The effects of biologic agents on humoral immunity, immunoglobulins, and vaccine response
  • Preventive and therapeutic strategies for infectious complications of biologic therapies

This activity will strengthen the ability of health care professionals to manage the constant challenge of balancing therapeutic immune suppression and the risk of infectious complications.

Objectives

At the conclusion of this activity, the participant will be able to:

  1. Explain possible clinical scenarios associated with infection in patients treated with biologic therapy.
  2. Identify possible strategies for managing treatment to reduce infectious events.

Target Audience

This activity is intended for rheumatologists, immunologists, and allied health care professionals, including nurses, nurse practitioners, and physician assistants, who care for patients with autoimmune diseases.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Continuing Medical Education for Category 2 credit.

Activity Director

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
RJ Fasenmyer Chair of Clinical Immunology
Theodore F Classen DO Chair of Osteopathic Research and Education
Vice Chairman, Department of Rheumatic and Immunologic Diseases
Cleveland, Ohio

Faculty

Jeffrey D. Greenberg, MD, MPH; R. John Looney, MD; Kevin L. Winthrop, MD, MPH

Faculty Disclosure

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:

Leonard H. Calabrese, DO
  Consulting, Teaching, and Speaking Abbott Laboratories; Amgen Inc.; Genentech, Inc.; Wyeth
 
  Consulting Elan Pharmaceuticals, Inc; F. Hoffman-La Roche, Ltd.
 
Jeffrey D. Greenberg, MD, MPH
  Consulting Bristol-Myers Squibb Company; Centocor, Inc.;
F. Hoffman-La Roche Ltd.; UCB Pharma
 
  Funded Research Bristol-Myers Squibb Company
 
R. John Looney, MD
  Consulting Amgen Inc.; Biogen Idec; Coley Pharmaceutical Group;
F. Hoffman-La Roche Ltd.; Genentech, Inc.;
MedImmune, Inc.; Trubion Pharmaceuticals, Inc.; Wyeth
 

The following faculty has indicated he has no relationship which, in the context of his presentation(s), could be perceived as a potential conflict of interest:

Kevin L. Winthrop, MD, MPH

The Cleveland Clinic Foundation Center for Continuing Education acknowledges an educational grant for support of this activity from:

Genentech, Inc. and Biogen Idec.

This CME activity was produced by The Cleveland Clinic Foundation Center for Continuing Education and IME, LLC.

CME Disclaimer

 
Bookmark this Chapter
Copyright © 2000-2009 The Cleveland Clinic Foundation. All Rights Reserved.
Center for Continuing Education | 9500 Euclid Avenue, KK31, Cleveland, OH 44195
Copyright © 2000-2009 The Cleveland Clinic Foundation. All Rights Reserved.
Center for Continuing Education | 9500 Euclid Avenue, KK31, Cleveland, OH 44195